An evaluation of Debrisan in chronic leg ulcers and pressure sores

Debrisan (Dextranomer) was subjected to a simple open assessment in the treatment of fifty-three chronic leg ulcers and thirty pressure sores in eight hospitals. It was found that 70% of leg ulcers and 76% of pressure sores improved, with a noticeable cleansing effect being evident in 79% and 83% respectively. No side-effects were recorded.